Quantcast

Latest antibodies Stories

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-06-10 16:27:52

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Antibody Partnering Terms and Agreementshttp://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The Antibody Partnering Terms and...

2014-06-10 00:22:14

BREDA, the Netherlands, GHENT, Belgium and WHITE PLAINS, New York, June 10, 2014 /PRNewswire/ -- arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead...

2014-06-05 12:31:16

MELBOURNE, Australia, June 5, 2014 /PRNewswire/ -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the oral presentation of data related to clinical development of NV-01, a novel canine monoclonal antibody (mAb) at a major upcoming veterinary meeting, the publication of a further peer-reviewed journal article regarding NV-01, and Nexvet's sponsorship of a pain management specialist veterinary meeting. 1. NC State Clinician Scientist Duncan Lascelles, BSc,...

2014-06-04 08:29:36

MUMBAI and LA CHAUX-DE-FONDS, Switzerland, June 4, 2014 /PRNewswire/ -- - State-of-the-art Manufacturing Facility for Supply of Clinical Trial Material - With the Facility Glenmark has end-to-end Capabilities for the Development of Novel, State-of-the-art Monoclonal Antibodies Including Bi-specific Antibodies Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP...

2014-06-04 04:21:39

BREDA, the Netherlands, June 4, 2014 /PRNewswire/ -- SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. Under the agreement, arGEN-X will bring its entire suite of...

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-05-28 08:31:16

MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb®7195. XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and...

2014-05-28 04:24:24

BREDA, The Netherlands, May 28, 2014 /PRNewswire/ -- arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to...

2014-05-27 23:11:01

Immunoglobulins or antibodies are proteins used by the immune system to neutralize pathogens including bacteria and viruses. The Life, Earth & Health Sciences Magazine EurekaMag.com has published 31,900 articles covering the interactions between a wide variety of immunoglobulins and pathogens particularly in humans. Mannheim, Germany (PRWEB) May 27, 2014 EurekaMag.com has published 31,900 articles on the importance of immunoglobulins for identifying and neutralizing pathogens such as...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related